L.Fend, et al. ESMO 2024 Abstract available on the CICON website – Download the abstract and the poster
Category: 2024
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Nominations
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
ESMO ABSTRACT
Transgene to Participate in HTID Conference and Investor Access Forum in Paris
investor events
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
Article available on The Journal for ImmunoTherapy of Cancer (JITC)
Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
TG6050
Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
current account advance
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
BT-001 ESMO 2024
Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
TG4050
Transgene’s Combined General Meeting of May 15, 2024
General meeting 2024
